drugset / Trial / NCT04615624

Furosemide vs. Placebo for Severe Antepartum Hypertension

NCT04615624

Phase 3 Completed 65 enrolled Melanie Maykin, MD
RandomizedParallel-groupTriple-blindTreatment

Summary

Primary objective: To determine whether the addition of intravenous furosemide with usual antihypertensives is associated with a reduction in mean systolic blood pressure from baseline compared to treatment with placebo plus usual antihypertensives (intravenous labetalol, intravenous hydralazine, or oral immediate release nifedipine) for the management of severe antepartum hypertension. Secondary objectives: To determine whether the addition of intravenous furosemide with usual antihypertensives is associated with a reduction in mean diastolic blood pressure compared to treatment with placebo plus usual antihypertensives listed above.

Timeline

Start
2021-01-04
Primary completion
2022-04-22
Completion
2022-04-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 40 mg Intravenous

Indications